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Abstract
Generalized anxiety disorder (GAD) is a common disorder associated with significant distress and 
interference. Although cognitive behavioral therapy (CBT) has been shown to the most effective 
form of psychotherapy, few patients receive or have access to this intervention. Yoga therapy offers 
another promising, yet under-researched, intervention that is gaining increasing popularity in the 
general public, as an anxiety reduction intervention. The purpose of this innovative clinical trial 
protocol is to investigate the efficacy of a Kundalini Yoga intervention, relative to CBT and a 
control condition. Kundalini yoga and CBT are compared with each other in a noninferiority test 
and both treatments are compared to stress education training, an attention control intervention, in 
superiority tests. The sample will consist of 230 individuals with a primary DSM-5 diagnosis of 
GAD. This randomized controlled trial will compare yoga (N = 95) to both CBT for GAD (N=95) 
and stress education (N = 40), a commonly used control condition. All three treatments will be 
administered by two instructors in a group format over 12 weekly sessions with four to six patients 
per group. Groups will be randomized using permuted block randomization, which will be 
stratified by site. Treatment outcome will be evaluated bi-weekly and at 6 month follow-up. 
Furthermore, potential mediators of treatment outcome will be investigated. Given the individual 
and economic burden associated with GAD, identifying accessible alternative behavioral 
treatments will have substantive public health implications.
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1. Introduction
Generalized anxiety disorder (GAD) has been determined to be one of the most ubiquitous 
anxiety disorders, with one-year prevalence rates ranging from 3% to 8% [1, 2]. In light of 
its prevalence, significantly deleterious impact on life functioning [3, 4], and high 
comorbidity[5–7], the identification and dissemination of efficacious treatments for GAD is 
imperative. Traditional cognitive behavior therapy (CBT) has received the most empirical 
support as an efficacious intervention for GAD [8]. Although CBT is a gold-standard 
treatment for anxiety disorders, it remains inaccessible to many patients. Several barriers 
deter individuals from undergoing empirically supported psychotherapy, including 
prohibitively exorbitant costs, the predominance of a face-to-face model of delivery, the 
paucity of available resources to address increasing mental health needs, etc. [9]. Current 
circumstances warrant the investigation of alternative treatment strategies to reduce this 
burden. A promising intervention that has become more widely adopted and accessible is 
yoga [10, 11]. Yoga, practiced in its traditional contemplative practice format, is a 
multicomponent behavioral practice incorporating physical postures and exercises, breath 
regulation practices, deep relaxation techniques, and meditation/mindfulness. In fact, a 
recent survey revealed that 8.9% of the population had used yoga as a therapeutic 
intervention and that yoga and its component practices of deep breathing and meditation 
were among the ten most prevalent alternative practices, as evidenced by its rapid adoption 
in the previous five years [11, 12].
Converging evidence underscores the presence of mindfulness deficits among individuals 
with GAD and other emotional disorders [13, 14]. Though several mindfulness based 
interventions currently exist (e.g., mindfulness based stress reduction (MBSR), mindfulness 
based cognitive behavioral therapy (MBCT), etc.) [15], difficulties in the dissemination of 
such treatments undermine their potential to reduce the overall burden of GAD. As yoga 
comprises several empirically supported components (e.g., meditation, breath regulation, 
physical exercise, and relaxation techniques) [16–18], it would be profitable to determine the 
efficacy of yoga in its full form. A thorough investigation of MBSR revealed that yoga 
exercises accounted for the largest contribution to treatment efficacy, despite being applied 
less than other MBSR components [19].
The therapeutic benefit of CBT and yoga is likely a consequence of differential treatment 
mechanisms. Extant literature attests to maladaptive cognitions as mediators of treatment 
change in CBT for anxiety disorders [20]. In virtue of the similarity between yoga and 
mindfulness based interventions, yoga likely conveys its effect by way of changes in 
mindfulness[21]. Basic research on yoga and its component techniques suggests it might 
facilitate reductions in arousal, targeting different mechanisms than does CBT [22–25]. 
Although there is evidence supporting the efficacy of yoga in reducing anxiety in general 
[26, 27], there are few trials of yoga for GAD, none of which are randomized controlled 
trials. Of the currently published uncontrolled trials reporting efficacy of yoga for GAD, two 
employed a yoga breathing intervention [28, 29], one employed a yoga mantra practice [30], 
and one applied an intervention combining CBT and Kundalini yoga practices [31]. The 
Kundalini yoga study showed statistically significant improvements in state and trait anxiety, 
depression, panic, sleep and quality of life with strong effect sizes for state and trait anxiety 
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[31]. In light of the paucity of high quality clinical trials of yoga for anxiety disorders, 
methodologically rigorous research undertakings are warranted to extend our current 
knowledge about the empirical status of yoga for GAD.
This paper describes the procedures and methodology of a five-year, multi-site randomized 
controlled trial investigating the comparative efficacy of yoga, CBT, and a stress education 
(SE) intervention, a frequently employed control condition for patients with GAD. The 
interventions will be administered over the course of twelve weeks. By employing a non-
inferiority test of yoga for GAD, the results of this study will inform current literature 
regarding its utility and efficacy.
2. Materials and Methods
2.1. Participants
To satisfy eligibility requirements for the current study, participants must be English fluent 
outpatients that are 18 years of age or older with a primary psychiatric diagnosis of GAD 
according to the criteria of the DSM-5. Comorbidity is permitted with other anxiety and 
depressive disorders, with the exception of concurrent post-traumatic stress disorder, 
substance use disorders, eating disorders, significant suicidal ideation, or an organic mental 
disorder. These exclusion criteria extend to individuals with a lifetime history of psychosis, 
bipolar disorder, or a developmental disorder.
To minimize confounds, participants are required to have limited prior experience with CBT 
and yoga (i.e., no more than five yoga classes or CBT sessions within the last five years). 
Though concomitant and prior pharmacotherapy is permitted, participants must undergo 
appropriate stabilization periods prior to treatment. Please refer to Table 1 for the complete 
catalogue of inclusion and exclusion criteria.
2.2. Recruitment and Screening Procedures
Participant recruitment will occur at the Center for Anxiety and Related Disorders at Boston 
University (CARD) and the Center for Anxiety and Traumatic Stress Disorders (CATSD) at 
Massachusetts General Hospital (MGH). Recruitment strategies will include advertisements 
in the media, postings online, particular email services, and clinical referrals from patients 
presenting at the abovementioned clinics. At CARD and MGH, we will post information on 
our respective clinic websites and distribute study information through the MGH All-User 
Broadcast and the RSVP for Health program.
Individuals who contact study personnel in either site will undergo an initial phone screen to 
determine potential eligibility and interest in research participation. Data for participants 
who undergo the phone screening process will be de-identified and recorded in the study 
database phone screening log. Furthermore, we will record reasons for ineligibility and for 
non-participation of eligible subjects. Interested patients who satisfy eligibility criteria will 
be scheduled for an evaluation meeting where informed consent will be obtained.
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2.3. Study Design
The purpose of the proposed randomized controlled trial is to examine the efficacy of yoga 
for GAD relative to standard psychosocial interventions. Using superiority tests, yoga (N = 
95) will be compared to SE (N = 40). Using non-inferiority tests, yoga will compared to 
standard CBT for GAD (N = 95). All three treatments will be administered by two 
therapists/yoga instructors/SE instructors in a group format over 12 weekly sessions with 4–
6 patients per group. For all interventions, a credible rationale for the efficacy of their 
assigned treatments, including SE, is provided, with all studies presented equally throughout 
the study. Various psychological measures will be completed by the participants at each 
study visit. The four independent evaluator blinded assessments occur pre-treatment 
(screening visit), mid-treatment (Week 6), post-treatment (Week 12), and at a six-month 
follow-up. Follow-up visits are scheduled at the termination of treatment to prevent attrition, 
and further contact is maintained to ensure patients’ availability for the follow-up visit.
2.4. Assessment Instruments and Procedures
All clinician-rated assessments will be undertaken by independent evaluators (IEs) blind to 
treatment assignment. The IEs will be M.D., Ph.D., or experienced Masters level 
diagnosticians experienced in the administration of structured clinical interviews who will 
receive further training and certification for this study under the direction of an IE trainer. 
Monthly inter-rater reliability checks for the assessments will be undertaken by IEs who did 
not conduct the initial interview. The ratings will be used to calculate kappa coefficients and 
to facilitate supervision, during which supervisors will discuss potential disagreement and 
provide instruction to enhance inter-rater reliability. Please refer to Table 2 for a schedule of 
assessment instruments.
As depicted in Table 2, the two Clinician Global Impressions Scales measuring symptom 
severity and symptom improvement (i.e., CGI-S and CGI-I, respectively) will be used for the 
primary analyses. More specifically, the primary outcome measure is the binary responder 
status value determined from the CGI-I, with a score of 1 (very much improved) or 2 (much 
improved) indicating responder status. The self-report measures of state anxiety, depression, 
worry, and quality of life constitute the secondary outcome measures. For the mediator 
analyses, we will be investigating whether self-report measures of mindfulness and 
metacognition andrespiratory sinus arrhythmia, mediate treatment outcome.
2.41 Primary Outcome Measures—Clinical Global Impression of Severity and 
Improvement (CGI-S, CGI-I; [33]): This two part clinician administered instrument assesses 
overall level of illness severity and level of symptom change across the course of treatment. 
The CGI-I ranges from 1 to 7, with scores less than 4 reflecting symptom improvement and 
scores greater than 4 indicating symptom worsening. A score of 1 (very much improved) or 
2 (much improved) defines treatment response.
2.42 Secondary Outcome Measures—State Trait Anxiety Inventory (STAI; [34]): The 
STAI is a 40-item, multiple-choice questionnaire that differentiates between the temporary 
condition of “state anxiety” and the more general and long-standing quality of “trait 
anxiety.”
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Beck Anxiety Inventory (BAI; [35]): This 21-item self-report inventory designed to measure 
severity of anxiety symptoms in psychiatric populations has high internal consistency and 
test-retest reliability. Beck Depression Inventory- Version II (BDI-II; [36]): The BDI-II 
contains 21 items that assess severity of depression symptoms in psychiatric populations has 
high internal consistency and test-retest reliability.
Perceived Stress Scale (PSS; [37]): This 10-item scale is the most widely used psychological 
instrument for measuring the perception of stress. It is a measure of the degree to which 
situations in one’s life are appraised as stressful.
Quality of Life Scale (WHOQOL-BREF; [38]): This instrument assesses quality of life and 
overall satisfaction.
Symptom Checklist Version 90 (SCL-90; [39]): The SCL-90 contains 90 items that assess to 
what degree certain problems and complaints bothered or distressed an individual during the 
past week. Penn State Worry Questionnaire (PSWQ; [40]): This instrument contains 15 
items that measure trait levels of worry. The PSWQ has excellent psychometric properties in 
student, community, and clinical samples.
Pittsburg Sleep Quality Index (PSQI; [41]): This is a 19-item measure of sleep quality over a 
one month duration. The items make up seven different component scores consisting of 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use 
of sleep medication and daytime dysfunction. This measure also generates a global sleep 
quality score.
Insomnia Severity Index (ISI; [42]): This 7-item instrument assesses symptoms of insomnia. 
Affective Style Questionnaire (ASQ; [43]): The ASQ contains 20 items that measures 
individual differences in emotion regulation. This instrument demonstrates good 
psychometric properties and comprises three subscales: concealing (i.e., habitual attempts to 
conceal affect), adjusting (i.e., adjusting emotions to be congruent with external goals), and 
tolerating (i.e., acceptance of emotions).
2.43 Mediators—Meta-Cognition Questionnaire (MCQ; [44]): This is a 65-item 
instrument used to assess meta-cognitive beliefs people have about their thinking styles.
Five Facet Mindfulness Questionnaire (FFMQ; [13, 45]): The FFMQ contains 39 items that 
assess five components of mindfulness, including observing, describing, acting with 
awareness, non-judging, and non-reacting. This scale has evidenced good psychometric 
properties and has been validated in clinical and non-clinical samples.
2.5. Treatment Interventions
All treatments were matched for time and attention; each treatment entails 120 minutes of 
training and practice in group sessions let by two instructors. Participants will receive a 
credible rationale for the efficacy of their assigned treatment. Participants in the CBT arm 
will be informed of the role of CBT in the efficacy of changing dysfunctional thought 
patterns and beliefs, those in the yoga arm will be informed of the role of yoga in changing 
cognitive and physical emotional and stress reactivity through the postures, breath regulation 
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and meditation components of yoga practice, and those in the SE control will be informed of 
the role of stress education in understanding the psychophysiological basis of stress and 
anxiety as a basis for overcoming stress and anxiety. All three interventions are standardized 
protocols with formalized treatment manuals for consistency.
2.5.1. Cognitive Behavioral Therapy—The 12 session CBT treatment will occur over 
the course of 12 sessions and will be derived from the standardized protocol developed at 
one of our centers (CARD) [46]. This intervention has received empirical support in both 
individual and group settings [47]. This protocol comprises four primary treatment modules 
including cognitive restructuring, progressive muscle relaxation, worry exposures, and in 
vivo exposure exercises. The initial sessions provide psychoeducation, elucidating the 
cognitive behavioral model of worry and GAD. Each session consists of a different “lesson”, 
which initially teaches basic information about the nature and possible function of the 
anxiety and worry, the negative consequences of sustained worrying, the maladaptive effects 
of attempting to suppress one’s thoughts, the basic cognitive errors of probability 
overestimation and catastrophic thinking, and adaptive strategies to successfully deal with 
worries. In addition, our treatment protocol will target meta-cognitions (i.e., worrying about 
worrying)[48]. Subjects will also be requested to complete approximately 20 minutes of 
homework daily, which will be recorded in a homework log.
2.5.2. Yoga—The yoga intervention will employ Kundalini Yoga as taught by Yogi Bhajan. 
Dr. Sat Bir Khalsa, one of the co-investigators who will train and supervise the instructors 
providing the yoga intervention, is a certified Kundalini Yoga instructor and has conducted 
clinical trials of yoga interventions. Kundalini yoga is a well-known, accessible yoga 
practice that includes physical postures and exercises, breathing techniques, relaxation 
exercises, and meditation practices. At study entry, subjects’ current physical health, 
flexibility and endurance will be assessed in the event that adjustments and modifications of 
the yoga practices need to be made to accommodate subject limitations. This yoga 
intervention will involve 12 weekly classes administered in group format led by qualified 
and certified Kundalini Yoga instructors. The weekly intervention itself entails yoga theory, 
philosophy and psychology, physical postures/exercises, breathing techniques, meditation, 
and deep relaxation practice, with the weekly group practices varying in content but 
increasing in intensity throughout the 12-week standardized protocol. Practices will include 
individual breathing practices (Sitali Breath, Alternate Nostril Breathing, Pauri Kriya), full 
hour-long Kundalini yoga sets/series (Basic Spinal Energy Series, Calmness and Anti-
anxiety Series, Stress Set for Adrenals and Kidneys) and individual yoga meditations with 
coordinated breathing (Segmented Breath for Anxiety, Tattva Balance Beyond Stress and 
Duality, Shabd Kriya) (accessible at the website: The Yogi Bhajan Library of Teachings, 
http://www.libraryofteachings.com/) Daily home practice assigned and instructed during the 
first treatment session will be facilitated with audio CDs to guide subjects throughout the 12-
week intervention. The same home practices will be used throughout in order for subjects to 
achieve mastery and self-efficacy. The 20-minute home practice session will begin with 
physical exercises for spinal flexibility and release of tension with coordinated breathing and 
maintenance of mind-body awareness, as follows: 1) seated spine flexes forward and back (1 
min), 2) seated spinal twists (2 min), 3) shoulder shrugs (2 min), 4) neck rolls in both 
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directions (2 min total), and 5) cat-cow spinal flexes on the hands and knees (2 min). These 
exercises are followed by the “Segmented Breath for Anxiety” involving slow, rhythmic, 
segmented inhales in 4 parts followed by segmented exhales in 8 parts maintaining a 1:2 
ratio between the duration of the inhales and the duration of the exhales for 11 min.
2.5.3. Stress Education Training—This intervention also entails 12 weeks of group and 
home practice sessions and will function as a control for attention from instructors, 
expectancy effects, and group support effects. In this condition, participants will receive 
extensive information about stress and health, but will not receive any of the active 
therapeutic ingredients used in CBT, yoga, or other mind-body training techniques. Instead, 
psychoeducational information will be provided, such as definitions of stress and the stress 
response, the fight or flight response, physiological and psychological effects of stress, stress 
and performance, the negative stress cycle, stress and health/illness, stress and immunity, 
stress buffers, stress hardiness, stress and heart disease, the role of genes and environment in 
health, the contribution of lifestyle behaviors such as caffeine and alcohol intake and 
cigarette smoking, and the importance of regular exercise and proper diet (without specific 
instructions for exercise or dietary changes). For the daily 20 minute home practice, subjects 
will listen to CDs that provide information about nutrition and positive perspectives on 
lifestyle and emotions.
2.6. Safety Protocol
In the service of optimizing safety for participants in the yoga and CBT interventions, we 
exclude all potential subjects with physical disabilities or cognitive disabilities severe 
enough to compromise safety or ability to participate in either of the interventions. For 
reasons of safety, all women of childbearing potential will be required to use a reliable form 
of birth control throughout the study, as there is insufficient information regarding the safety 
of yoga during pregnancy. Adverse events will be assessed at each visit by inquiring whether 
any major change in mental or physical health occurred since the participant’s previous visit. 
Furthermore, the clinical global impression of severity scale (CGI-S), clinical global 
impression of improvement (CGI-I), Beck Depression Inventory (BDI-II), and a suicide risk 
assessment will be administered to evaluate any potential worsening symptoms biweekly 
from baseline to termination of treatment.
Any participant with a CGI-I of 5 or greater at any time will undergo weekly assessment by 
a study clinician including clinical and safety assessments, CGI-S and CGI-I ratings, and 
suicidality assessment. To ensure participants are able to benefit from some form of 
treatment, we will discontinue participants who endorse ‘much worse’ (i.e., >5) on the CGI-I 
for 2 consecutive weeks or who develop significant suicidality at any point. Appropriate 
referrals will be made to ensure they receive care from certified mental health providers. In 
addition, if the BDI-II suicidality item (i.e., item number 9) exceeds 1 or the CSS suicide 
checklist exceeds 2, the patient will be assessed weekly to monitor suicidality and receive 
any indicated clinical intervention.
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2.7. Fidelity Monitoring
All of the group intervention sessions will be audio recorded. We will rate 20% of the 
recordings for adherence and fidelity to ensure that individuals receive the form of treatment 
appropriate to their assigned group. Failure to satisfy minimum standards (i.e., receives an 
adherence or competence rating below the certification standard for 2 consecutive sessions 
(≤5 for adherence, ≤3 for competence)), will be redressed with supplemental training 
provided by the supervising clinician. Furthermore, the next two sessions will be reviewed to 
appraise whether they meet certification standards. In the unlikely event therapists do not 
meet these standards, they will be replaced.
2.8. Data Analytic Strategy
Randomization will be stratified by site. Treatment groups will assigned using a permuted 
block randomization for each site. One block will be generated for each site. Conservatively 
assuming an average of 4 participants per treatment group, the block will consist of 12 Yoga 
groups, 12 CBT groups, and 5 SE groups to achieve the appropriate allocation ratio of 
participants to treatment conditions. We will use the Sealed Envelope program to generate 
the randomization. After all participants in a potential treatment group have completed their 
baseline assessment, the study coordinator will inform the study statistician that the next 
group is ready for randomization, and the statistician will then inform the treatment 
coordinator of the randomization for that group..
Our primary analyses will use mixed-effects regression models (MRMs) with a logistic 
linking function, a general linear mixed model (GLMM) analysis, as our primary outcome 
measure (response to treatment, defined as CGI-I≤2) is dichotomous. Analyses of secondary 
outcomes will be performed using MRM. MRM and GLMM easily accommodate nesting of 
repeated observations within subjects, include all subjects with at least one assessment, and 
are the preferred method to analyze longitudinal data [50]. Since these analyses will include 
all subjects who are randomized and complete at least one assessment, it is an intent-to-treat 
analysis. Also, since subjects will undergo treatment in groups, our MRM and GLMM 
models will include 3 levels: repeated measurements (level 1) nested within subjects (level 
2) who will be nested within their treatment cohort (level 3).
The three treatment conditions (yoga, CBT, and SE) will be coded using 2 dummy variable 
contrasts, with SE as the “reference” treatment. The first dummy variable will contrast yoga 
vs. SE, and the second will contrast CBT to SE. Time will be centered at week 12 and coded 
as weeks since baseline. In MRM or GLMM analyses in which this Time centered variable 
is used, the significance of the dummy variable contrasts (yoga vs. SE and CBT vs. SE) 
provides the test of the differences between these treatment conditions at post-treatment. A 
similar approach can be used to test differences between treatment conditions at follow-up.
The mediation analysis includes 2 independent variables (i.e., the contrast of yoga vs. SE 
and the contrast of CBT vs. SE) and 3 mediators: mindfulness, vagal tone, and maladaptive 
cognitions. The 3 mediators will be included in the growth curve model as additional 
simultaneous predictors of response. Significance of mediated pathways will be determined 
using bias-corrected bootstrap mediation analysis [51]. We predict that changes in 
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mindfulness will mediate changes in outcome over time for patients in the yoga condition, 
and changes in cognitions will mediate changes in CBT. Plus, changes in RSA and cortisol 
may also mediate changes in outcome across conditions.
To address missing data, we will use pattern mixture modeling [52, 53] and re-conduct the 
analyses to identify potential missing data patterns (e.g., no missing data, early dropouts, 
late dropouts, FU dropouts, etc.) and determine whether missingness influences our findings.
2.9. Sample Size
The sample will consist of 230 patients with a primary DSM-5 diagnosis of GAD. We will 
compare yoga (N = 95) to both CBT for GAD (N=95) and stress education (SE) (N = 40), a 
commonly used attention control condition [54]. To directly appraise our hypothesis that 
yoga will have comparable short-term and long-term efficacy with that of CBT, we will 
adopt a non-inferiority test framework for the primary outcome, which is the binary 
responder status value determined from the CGI-I, with a score equal to or less than 2 
indicating responder status. To address potential attrition, we will conduct an intent-to-treat 
analysis. The non-inferiority margin will be half the difference in response rates between the 
active comparison (CBT) and control condition. In accord with prior literature, we estimated 
response rates for our particular interventions (i.e. 57.9% in CBT and 22.2% in control). 
Thus, our non-inferiority margin will be set at half the difference between 57.9 and 22.2, or 
17.85%. Using the power analysis program PASS 12 [55], we determined that the number of 
subjects required to obtain .80 power for the non-inferiority test comparing CBT and yoga is 
95 participants in each of the 2 conditions.
For the superiority tests on responder status (a greater proportion of participants will respond 
to treatment in CBT and in Yoga than in SE), we will use GLMM with a logistic linking 
function. We performed various Monte Carlo simulations to determine the smallest 
percentage difference between the treatments and the control group that we could detect 
with .80 power. Assuming a sample size of 230 and 25% missing data, we found that we 
could detect a difference in response rate as little as 22% between the treatments and the 
control (e.g., if the control response rate was 22.2%, we have .80 power to detect a 
significant difference between either treatment condition and the control condition if the 
treatment condition response rate is 44.2% or higher). This difference is equivalent to an 
effect size of ω=24, smaller than a medium effect size (a medium effect size for proportions 
is ω=.30, and a small effect size is ω=.10).
For the superiority tests (CBT vs. SE and Yoga vs. SE) on the secondary outcomes (which 
are the continuous self-report measures presented in Table 2), we used the mixed-effects 
regression models (MRM) power analysis program PinT 2.12 [56]. We assumed 25% 
missing data, and used data from our recent CBT trials [57] to estimate the variances and 
covariances needed for PinT. PinT indicated greater than .80 power to detect an effect size as 
small as d=0.27, between a small (d=0.20) and medium (d=0.50) effect size.
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3. Discussion
The study will examine the efficacy of Kundalini Yoga for GAD as compared to CBT and a 
psychological attention control condition. Extant literature suggests that CBT conveys its 
therapeutic effect, in part, through modification of maladaptive cognitions [20]. Yoga entails 
the cultivation of physical and psychological health through a variety of techniques 
including physical posture exercises, breathing exercises, relaxation strategies, and 
meditation practice. As mindfulness based interventions comprise several of these 
components [58], we hypothesize that increases in mindfulness will function as a core 
treatment mechanism in yoga. Furthermore, we are evaluating the presence of biological 
mechanisms in yoga, namely vagal tone. The chief pathological process underling GAD is 
worry. Several studies have established that excessive worry entails reduced autonomic 
flexibility as a result of low cardiac vagal tone [59, 60]. Assessment of this biomarker is 
accomplished by recording respiratory sinus arrhythmia, which reflects rhythmic variations 
in heart rate that occur at the frequency of respiration. Because yoga exercises emphasize 
breathing techniques, we predict that symptom improvement will also be a consequence of 
changes in vagal tone. By ascertaining the chief mechanisms responsible for treatment 
efficacy, the results of the current study can facilitate the development of more 
parsimonious, effective treatments for GAD.
Adopting a randomized controlled trial design provides a stringent experimental framework 
to examine our hypotheses. Moreover, the data analytic and methodological strategies used 
in the current study include prospective efforts to address potential limitations related to 
attrition. To retain sufficient power for group comparisons, our initial sample size was 
estimated under the assumption of 25% missing data, and our complementary use of mixed-
effects regression models and pattern mixture modelling will foster greater confidence in the 
validity of our results. Certain limitations do warrant mention, however. It would be 
desirable to assess our proposed mechanisms more frequently, which would provide a more 
robust test of mediation. As these variables are measured at pre-, mid-, and post-treatment, 
the current study might be unable to discern whether changes in the mediator variables 
precede improvement in symptoms [61]. Though our mediational hypotheses represent only 
a secondary aim, we recommend that future research measure mediator variables at more 
frequent time points to better establish temporal precedence.
Although there are several empirically supported behavioral and pharmacological 
interventions that ameliorate symptoms of GAD [62], there may be a distinct opportunity to 
contribute to the provision of care by exploring alternative treatments. Given the great deal 
of overlap between yoga and other empirically supported interventions (i.e., mindfulness 
based interventions), there may be potential for yoga to have a substantive impact on the 
clinical and economic burden posed by GAD. The current research endeavor represents an 
innovative effort to address clinically and scientifically relevant questions related to the 
treatment of GAD. In addition, it will provide a rigorous test of the efficacy of yoga for a 
prevalent mental health condition.
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Table 1
Inclusion and Exclusion Criteria and Rationale.
Inclusion Criteria Rationale
Male or female outpatients 18 years of age or older with a primary psychiatric diagnosis of 
generalized anxiety disorder
Population under study
CGI-severity score of 4 or higher Adequate pre-treatment severity
Off concurrent psychotropic medication for at least 2 weeks prior to initiation of randomized 
treatment, OR stable on current medication for a minimum of 6 weeks and willing to maintain a 
stable dose
Treatment confound
Willingness and ability to perform the yoga intervention and to comply with the requirements of the 
study protocol.
Human subjects concerns
For women of childbearing potential, willingness to use a reliable form of birth control Human subjects safety
Exclusion Criteria
Patients unable to understand study procedures and participate in the informed consent process. Human subjects concern
Pregnancy as assessed by a urine pregnancy test at screen for women of childbearing age Human Subjects Safety
Women who are planning to become pregnant. Human Subjects Safety
Serious medical illness or instability for which hospitalization may be likely within the next year Feasibility, subject safety
Significant current suicidal ideation or suicidal behaviors within the past 6 months (assessed with the 
BDI-II)
Subject safety
History of head trauma causing loss of consciousness, or seizure disorder resulting in ongoing 
cognitive impairment
Treatment confound, subject safety
Posttraumatic stress disorder, substance use disorder, eating disorder, or organic mental disorder 
within the past 6 months
Treatment confound
Lifetime history of psychotic disorder, bipolar disorder, or developmental disorder Treatment confound
Significant personality dysfunction likely to interfere with study participation (assessed during the 
clinical interview)
Treatment confound
Prior experience with (more than 5 Yoga classes or CBT sessions within the last 3 years) and/or 
current practice of mind-body techniques (e.g., yoga, meditation, Tai-Chi, etc) or CBT
Treatment confound
Concomitant psychotherapy for GAD (any psychotherapy) Treatment confound
Physical conditions that might cause injury from yoga (pregnancy, physical injuries and 
musculoskeletal problems)
Human subjects concern and subject 
safety
Cognitive impairment (MOCA≤21) Human subjects concern and safety
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